Navigation Links
Abide Therapeutics Announces Collaboration With Merck to Develop Novel Therapies for Type 2 Diabetes and Metabolic Diseases
Date:5/2/2013

SAN DIEGO, May 02, 2013 /PRNewswire/ -- Abide Therapeutics, a biopharmaceutical company pioneering innovative approaches to selectively target a group of enzymes known as serine hydrolases, today announced that it has entered into a collaboration agreement with Merck, known as MSD outside the U.S. and Canada, to discover, develop and commercialize small-molecule therapies directed against three novel targets to treat metabolic diseases with a focus on type 2 diabetes.

(Logo: http://photos.prnewswire.com/prnh/20130502/LA06084LOGO)

"This collaboration leverages Abide's unique and innovative therapeutic engine," said Alan Ezekowitz , MBChB, D.Phil., President and CEO of Abide Therapeutics.  "We are eager to validate unique targets that we hope will lead to the development of novel therapeutics that will benefit patients with diabetes and metabolic diseases." 

Under the terms of the agreement, Abide Therapeutics is eligible to receive an upfront payment, research funding, and potential milestone payments for up to $430 million for three products. Further details of the financial terms were not disclosed. Merck will have worldwide commercialization rights to any products that may be developed as a result of the collaboration. Abide Therapeutics is entitled to receive royalty payments on global sales from any such products.

"Diabetes and related disorders continue to represent a significant global, unmet medical need," said Nancy Thornberry , Senior Vice President and Franchise Head, Diabetes and Metabolism, Merck Research Laboratories. "We look forward to working with Abide on the discovery and development of important new medicines."

About Serine Hydrolases

The large family of serine hydrolases are validated but largely under explored as drug targets. These enzymes play a key regulatory role in human physiological processes, such as regulating CNS signaling, digestion, metabolism, inflammation, blood clotting, and life cycle of viruses and pathogens. Thus, the ability to target serine hydrolases has broad therapeutic applications. The proprietary Abide technology platform provides a unique highly selective small molecule collection that specifically targets the common catalytic site of serine hydrolases.  The technology provides a rapid and effective method for target identification and validation.  

About Abide Therapeutics

Abide Therapeutics is focused on developing innovative medicines that target serine hydrolases, one of the largest enzyme classes in nature with validated but mostly untapped therapeutic potential. Serine hydrolases play important regulatory roles in human physiology and disease. Abide has created a proprietary platform, based on technology developed at The Scripps Research Institute by Professors Ben Cravatt and Dale Boger , that specifically targets serine hydrolases with selective small molecules. The ability to target and modulate serine hydrolases has potential to develop new medicines in many therapeutic areas.  Abide is located in San Diego.  To learn more, visit www.abidetx.com


'/>"/>
SOURCE Abide Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Algeta and Lumiphore Announce Further Expansion of Their Global Partnership for the Development of Targeted Alpha-pharmaceutical Cancer Therapeutics and Companion Diagnostics.
2. Combination Drugs are the Future of the European Hepatitis B and C Therapeutics Markets, Says Frost & Sullivan
3. SMaRT Therapeutics Announces Appointment of Dr. John H. Abeles to the Advisory Board
4. Inhibikase Therapeutics to present at 5th International Congress on Polyomaviruses and Human Diseases
5. Immunomic Therapeutics Announces Interim Data Analysis of Phase I Study to Treat Japanese Red Cedar Allergy
6. PTC Therapeutics Appoints Mark Rothera As Chief Commercial Officer
7. DSM and DecImmune Therapeutics Sign Agreement to Develop N2 Pathway Blocking Antibody
8. Serina Therapeutics Announces Agreement Retaining Woodside Capital Partners as Advisor and Investment Bank
9. Serina Therapeutics Announces Worldwide Exclusive License Agreement with The Scripps Research Institute for Click Chemistry
10. Mast Therapeutics Presents MST-188 Data at 7Th Annual Sickle Cell Disease Research and Educational Symposium
11. Society for Brain Mapping and Therapeutics (SBMT) announce the formation of American Board of Brain Mapping, its 2013 award recipients and its Brain Mapping Day at the US Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/8/2017)...   Responding to Heath Ledger,s father,s recent ... singer Chris Cornell in May, the mental health ... free online psychiatric drug side effects search ... psychotropic drug risks. The father of the ... accidental overdose, has called for tighter rules on prescription drugs. ...
(Date:6/7/2017)... , June 7, 2017 Endo International plc ... 7, 2017, the Hon. Joseph R. Goodwin , ... West Virginia , entered a case ... Pelvic Repair System Products Liability Litigation (the "MDL") that ... cases to provide expert disclosures on specific causation within ...
(Date:6/7/2017)... 6, 2017  Diplomat Specialty Infusion Group, a brand of Diplomat ... its Iowa location. The ... now features an ISO 7 cleanroom—the standard needed to compound intravenous ... low level of pollutants. "Our ... and better serve our Iowa patients," said ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... ... Ross Insurance Agency ( http://www.rossinsuranceagency.com ) saves clients thousands ... recent update of flood zones, more people than ever are in flood zone ... reflect the actual risk in flood zone areas during a time when FEMA ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Katyl Agency, a locally ... and business owners in and around Lackawanna County, is joining Meals On Wheels ... area. , Meals on Wheels of NEPA provides hand-delivered and nutritious meals to ...
(Date:6/23/2017)... Morgantown, WV (PRWEB) , ... June 23, 2017 ... ... asset protection services and personal financial planning to families and business owners in ... Stepping Stones organization to help provide services to differently abled residents in the ...
(Date:6/22/2017)... ... June 22, 2017 , ... Plastic Surgery Associates is proud ... Doctor for 2017. Each year, research and information firm, Castle Connolly, releases their list ... in 2015, this marks the 3rd time that Dr. Canales has been ...
(Date:6/22/2017)... ... 22, 2017 , ... Children’s National Health System ... to launch a Rheumatic Heart Disease Center, with the goal of developing innovative ... disease (RHD) in high-risk, financially disadvantaged countries and low-income communities across the United ...
Breaking Medicine News(10 mins):